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Abstract
Background: Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is a benign lymphoid proliferation or
malignant lymphoma in patients who have been treated with MTX. MTX withdrawal and observation for a short
period should be considered in the initial management of patients who develop LPD while on MTX therapy. Here
we evaluated the diagnostic accuracy and predictive value of 18F-fluorodeoxyglucose positron emission
tomography/computed tomography (18F-FDG PET/CT) for MTX-LPD.
Methods: We retrospectively investigated the cases of 15 patients clinically suspected of having MTX-LPD. A total of
324 anatomic regions (207 nodal and 117 extranodal regions) were assessed by 18F-FDG PET/CT and by multi-detector
row CT (MDCT). Each anatomic region was classified as either malignant or benign. The uptake of 18F-FDG was
assessed semi-quantitatively with the standardized uptake value maximum (SUVmax), the whole-body metabolic tumor
volume (WBMTV), and the whole-body total lesion glycolysis (WBTLG) in order to investigate predictive factors of
spontaneous regression after the withdrawal of MTX.
Results: MTX-LPD lesions were observed in 92/324 (28.4 %) regions. 18F-FDG PET/CT showed 90.2 % sensitivity, 97.4 %
specificity, and 95.4 % accuracy, values which were significantly higher than those of MDCT (59.8, 94.8, and 84.9 %,
respectively. p < 0.002). After the withdrawal of MTX, 9/15 patients (60.0 %) achieved complete response (CR). The
SUVmax, WBMTV and WBTLG values of the CR patients were 9.2 (range 2.8–47.1), 44.3 (range 0–362.6) ml, 181.8 (range
0–2180.9) ml, respectively, which were not significantly different from those of the non-CR patients: 10.6 (range 0–24.9),
15.7 (range 0–250.1) ml, and 97.4 (range 0–1052.1) ml.
Conclusions: Although 18F-FDG PET/CT was a useful tool to detect MTX-LPD lesions, none of the 18F-FDG PET
parameters before the withdrawal of MTX could be used to predict CR after the withdrawal of MTX.
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(MTX-LPD) is a rare benign lymphoid proliferation or
malignant lymphoma observed in patients who have
been treated with MTX. It was first reported in 1991 [1]
and is now defined by the World Health Organization
(WHO) as among the “immunodeficiency-associated
LPDs” [2]. MTX is typically administered as a treatment
for inflammatory diseases, especially rheumatoid arth-
ritis (RA), and it has been an anchor drug in the treat-
ment of RA. There are many reports and case series of
MTX-LPD spontaneously regressing shortly after the
discontinuation of MTX [3–6]. It was also reported that
only histology and Epstein-Barr virus (EBV) positivity
were useful for predicting clinical outcomes in patients
with RA-LPD [7].
18F-fluorodeoxyglucose (18F-FDG) positron emission
tomography/computed tomography (PET/CT) is an in-
dispensable tool that can detect metabolically active dis-
ease in the whole body, with increased diagnostic
accuracy in malignant disease. Thus, 18F-FDG PET/CT
has been reported to provide superior information for
the staging of non-Hodgkin lymphoma (NHL) compared
to conventional CT scans [8–10]. The volume-based pa-
rameters from 18F-FDG PET, such as the maximum
standardized uptake value (SUVmax), the whole-body
metabolic tumor volume (WBMTV) and whole-body
total lesion glycolysis (WBTLG) have been reported to
be useful for making a detailed prediction of the progno-
sis in patients suffering from various types of lymphoma
[11–14]. These studies indicated that high metabolic ac-
tivity might be useful when considering candidates for
aggressive therapy and for identifying patients at in-
creased risk for relapse after therapy. However, there
have been very limited reports about a clinical role of
18F-FDG PET/CT in MTX-LPD [4], and no study has
examined the relationships between the prognosis of
MTX-LPD and 18F-FDG PET parameters such as SUV-
max, WBMTV, and WBTLG.
The treatment for immunodeficiency-associated LPD
in patients treated with MTX is to stop the immunosup-
pressive condition by discontinuing the MTX, which dif-
fers from the treatment for NHL. Although no strict
guidelines for the treatment of MTX-LPD have been
established, the withdrawal of MTX and the use of
observation-alone have usually been considered to be
beneficial [7, 15–17]. Unfortunately, there is a subgroup
of patients who do not respond to MTX withdrawal and
need cytotoxic chemotherapies. Being able to predict
spontaneous regression before the withdrawal of MTX
would be greatly beneficial, as unnecessary cytotoxic
therapies could then be avoided.
The first purpose of the present study was to investi-
gate the diagnostic accuracy of 18F-FDG PET/CT
compared to that of multidetector row CT (MDCT) for
MTX-LPD. The second purpose was to determine
whether 18F-FDG PET parameters could predict a
complete response (CR) after the withdrawal of MTX.
Methods
Subjects
This retrospective study was approved by the institu-
tional review board (#013-0422).
We retrospectively analyzed the imaging reports of the
patients suspected of having MTX-LPD who underwent
PET/CT scanning at Hokkaido University Hospital
during the period from June 2009 to December 2014.
We searched the electronic database of all PET/CT scans
performed during this time period to identify the pa-
tients suspected of having MTX-LPD, and the clinical or
histological diagnosis was confirmed by review of each
patient’s electronic medical records.
A total of 26 patients suspected of having MTX-LPD
were identified by the review. The diagnosis of MTX-LPD
was made in 22 of these patients. Regarding the other
three patients, they were diagnosed with other pathologies
(i.e., lung cancer, chronic lymphocytic leukemia, reactive
lymph node in one patient each), and the association
between MTX treatment and the remaining diagnosed
plasma cytoma was unclear; these patients were therefore
excluded from the analyses. We also excluded the cases of
five patients who were followed up or received additional
therapy at another hospital and two patients whose MTX
was withdrawn before FDG PET/CT. The final study
population was 15 patients with MTX-LPD (62.0 ±
10.7 years old, five men, ten women). Their characteristics
are summarized in Table 1. The reasons for MTX therapy
were RA (n = 13), polyarteritis nodosa (n = 1), and psori-
atic arthritis (n = 1). The mean duration of MTX treat-
ment was 84.1 ± 59.6 months (range 7–234 months).
Nodal regions of lymphoma were observed in 11 of the 15
patients. Extranodal regions of lymphoma were observed
in eight of the patients, including the gingiva (n = 2), skin/
subcutaneous site (n = 4), lung (n = 4), liver (n = 2), peri-
cardium (n = 1), bowel (n = 1), bone (n = 1), tonsil (n = 1)
and adrenal (n = 1).
Pathological data were obtained using tissue specimens
obtained by biopsy or resection from 11 patients. The
other four patients were diagnosed based on their clin-
ical course. The pathologically confirmed histological
types were diffuse large B-cell lymphoma (n = 5), pleo-
morphic B-cell lymphoproliferative disease (n = 3), fol-
licular lymphoma (n = 1), mucosa-associated lymphoid
tissue lymphoma (n = 1), and marginal zone lymphoma
(n = 1). After the withdrawal of MTX, nine of the 15 pa-
tients (60.0 %) achieved a CR, and the other six patients
(40.0 %) were non-CR. The mean follow-up duration
was 31.7 ± 19.4 months (range 9–67 months).
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Assessment of clinical information
The histopathological diagnosis was determined on the
basis of the WHO lymphoma classification criteria [2] for
the 11 patients whose pathological data were available. In
addition to hematoxylin-eosin staining, immunohisto-
chemical staining, flow cytometry analysis, and an EBV in
situ hybridization analysis were performed for pathologic
confirmation. The follow-up evaluation was established
on the basis of the clinical follow-up, which included clin-
ical examinations, ultrasonography, contrast-enhanced
CT, 18F-FDG PET /CT scanning, or an additional biopsy
every 1–3 months.
CR definition
In this study, the patient outcome was defined as a CR
when all lesions of MTX-LPD had disappeared after the
withdrawal of MTX without cytotoxic treatment (i.e.,
chemotherapy and radiotherapy) during the follow-up.
The patient outcome was defined as non-CR when add-
itional chemotherapy was needed to treat the residual
tumor after the withdrawal of MTX or the patient had re-
sidual tumor or a recurrence during the follow-up period.
We defined the clinical outcome at the time of our review.
PET/CT imaging
All patients underwent 18F-FDG PET/CT acquisitions
using an integrated PET/CT scanner (Biograph 64 PET/
CT scanner, Asahi-Siemens Medical Technologies,
Tokyo). Before tracer injection, the patient fasted for at
least 6 h. Following a blood glucose test to confirm
blood glucose levels less than 150 mg/dL, PET images
were acquired 60 min after an intravenous injection of
18F-FDG (4–5 MBq/kg). Emission scanning for 3 min
per bed was carried out following the CT image acquisi-
tion for attenuation corrections.
The acquired datasets were corrected for attenuation,
dead-time and scatter, and the images were reconstructed
using a point spread function-based iterative algorithm
(TrueX, Siemens) [18] with two iterations per 21 subsets
with 512 × 512-pixel matrix, a matrix size of 168 × 168, a
voxel size of 4.1 × 4.1 × 2.0 mm, and a Gaussian filter at
4.0- mm full-width at half-maximum. The transaxial and
axial field of views were 58.5 cm and 21.6 cm, respectively.
MDCT imaging
All patients were scanned with either a 64-slice or a
320-slice multi-detector row CT scanner. Six patients
underwent a contrast-enhanced scan. These patients re-
ceived an intravenous injection of iodine contrast agent
(450–560 mgI/kg) at a rate of 2–3 mL/s using a power
injector, and CT images were obtained approx. 60 s fol-
lowing the injection. The other nine patients underwent
a non-contrast enhanced MDCT scan. The scan range of
12 patients was from the middle of the skull to the mid-
thigh. The scan range of the other patients was the cer-
vical region only, the abdominal region only, or from the
cervical to chest region. Axial CT images were recon-
structed using a 5-mm section thickness.
Table 1 Characteristics of the 15 patients with MTX-LPD















1 70s RA 48 8 259 212 0 FL - I 1 non-CR
2 70s RA 138 6 5861 190 3 DLBCL - IV 4 non-CR
3 60s RA 234 8 3744 292 3 - + III 4 non-CR
4 70s RA 103 6 310 241 1 MALT lymphoma N/A II 2 CR
5 60s PN 40 15 670 254 1 DLBCL + IV 4 non-CR
6 50s PA 83 10 3157 336 2 - + IV 3 CR
7 50s RA 101 10 737 229 0 polymorphic BLPD - III 1 non-CR
8 70s RA 50 8 864 209 1 polymorphic BLPD + IV 3 CR
9 70s RA 13 4 503 221 1 DLBCL - IE 1 CR
10 40s RA 7 8 758 149 0 - N/A II 0 CR
11 50s RA 48 6 340 176 1 polymorphic BLPD + IIE 0 CR
12 40s RA 48 16 1370 192 1 - - III 1 CR
13 60s RA 116 8 1136 242 1 DLBCL - IV 3 CR
14 50s RA 60 16 852 231 1 MZL + IV 3 non-CR
15 60s RA 172 8 402 252 0 DLBCL + IV 4 CR
BLPD B-cell lymphoproliferative disease, CR complete response, DLBCL diffuse large B-cell lymphoma, EBV Epstein-Barr virus, F female, FL follicular lymphoma, IPI
International Prognosis Index, LDH lactate dehydrogenase, M male, MTX methotrexate, MZL marginal zone lymphoma, N/A not available, PA psoriatic arthritis, PN
polyarteritis nodosa, PS performance status, sIL-2R soluble interleukin-2 receptor
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Image analyses
Each patient’s disease stage was determined by the Ann
Arbor classification system for malignant lymphoma
[19]. Staging was confirmed by clinical follow-up or bi-
opsy. We also divided the whole body into 16 nodal re-
gions and nine extranodal anatomic regions for analysis,
in accord with previous studies [20–22] (Table 2).
We compared each patient’s FDG-PET/CT findings
with the results of the corresponding imaging examina-
tions in terms of the presence of MTX-LPD disease. We
classified the findings as follows. TP: true-positive (pres-
ence of MTX-LPD), TN: true-negative (absence of
MTX-LPD), FP: false-positive (abnormal FDG uptake
unrelated to MTX-LPD), or FN: false-negative (missed
diagnosis of proved MTX-LPD) according to the refer-
ence standard. The reference standard included histo-
pathologic findings (obtained by biopsy) or informative
follow-up (clinical, laboratory, PET/CT, or other imaging
findings such as endoscopy, MRI, and ultrasonography).
It was impossible to obtain histopathologic proof of all
of the suspected lesions in most of the clinical situations,
especially in the patients with systemic disease spread.
We therefore set the reference standard by using the
method comparing PET/CT and MDCT findings in
studies similar to ours [23, 24].
For example, in the case of a patient entering remis-
sion, lesions that were resolved on follow-up imaging
were considered TP, and lesions that remained stable or
progressed were considered FP. In the case of a patient
experiencing disease progression, lesions that progressed
were considered TP, and lesions that resolved or
remained stable on follow-up imaging were considered
FP. A region was considered FN if a lesion was not seen
by one modality but was identified by another modality
and met the criteria for a TP result as described above.
A region was considered an FN if lesions were seen but
were considered non-malignant on FDG-PET/CT or
MDCT and disease developed at the same site of follow-
up. Regions were considered TN when the site remained
disease-free at the follow-up after MTX withdrawal.
The clinical images were independently evaluated in
random order by two nuclear medicine physicians (S.W.
and O.M.) for 18F-FDG PET/CT and two diagnostic radi-
ologists (Y.K. and N.M.) for MDCT. The readers were
blinded to all clinical information, the results of the
other imaging modalities, such as endoscopy, MRI, and
ultrasonography before MTX withdrawal, and the evalu-
ation by the other reader.
Thirty-three lymph node regions and 18 extranodal ana-
tomic regions were out of the field of view of the anatom-
ical CT scanning. Therefore, a final total of 207 lymph
node regions and 117 extranodal anatomic regions were
analyzed. Areas with focally increased 18F-FDG uptake
were considered to be sites of active disease for PET/CT.
For the MDCT analysis, abnormal lymph nodes were de-
fined as having a minimum dia. >1 cm and extranodal le-
sion as mass lesions considered as equivocal or positive
for malignancy. All regions were evaluated as positive or
negative. If there was a discordant finding between the
two readers, consensus was obtained by discussion. Le-
sions considered positive, suggestive or equivocal for
MTX-LPD were considered positive for the analysis. Le-
sions reported as unlikely or negative for MTX-LPD were
considered negative for the analysis. The number of
disease sites was evaluated by each physician.
In addition, one nuclear medicine physician (S.W.)
assessed the 18F-FDG PET images using semi-quantitative
methods. The SUVmax from the single pixel showing the
highest FDG accumulation in the lesion was calculated to
obtain the information of tumor activity, as [tissue radio-
activity concentration (Bq/ml)] × [body weight (g)] /
[injected radioactivity (Bq)]. Two volume-based parame-
ters, the WBMTV and the WBTLG, were also measured.
The WBMTV was calculated from the 18F-FDG PET
images according to the following procedure. First, the
boundaries of voxels with an SUV intensity exceeding 2.5
were produced automatically. Second, the physiological
uptake including that in the brain, oral cavity, pharynx,
heart, stomach, liver, intestines, kidney, ureter, bladder,
skeletal muscle, and any other tissues was carefully
subtracted by the nuclear medicine physician. Third, false-
positive lesions, such as inflammation of joints or other
benign 18F-FDG-avid lesions based on MDCT or follow-
up studies including physiological examination, MDCT,
ultrasonography and PET/CT scan were subtracted.
Table 2 Nodal and extranodal regions for region-based analysis
Nodal regions (n = 16) Extranodal regions (n = 9)
Waldeyer ring Upper aerodigestive tract
Right necka Skin/subcutaneous
Left necka Central nervous system and spinal canal
Right infraclavicular Lung
Left infraclavicular Myocardium
Right axillary and pectoral Bone and bone marrow
Left axillary and pectoral Liver
Mediastinal Bowel






Right inguinal and femoral
Left inguinal and femoral
aIncluded cervical, supraclavicular, occipital, and preauricular regions
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Finally, the total lesion glycolysis (TLG) value was calcu-
lated for every target lesion as TLG =MTV× SUVmean,
and the WBTLG was calculated as the total of TLG in the
entire body.
Statistical analysis
Data are expressed as the median and range. Differences
in the SUVmax, WBMTV and WBTLG between two
groups were tested using Welch’s t-test for categorical
variables. A Bowker test was used to compare the accur-
acy of 18F-FDG PET/CT scans and MDCTs in detecting
malignant lesions. For each analysis, p-values <0.05 were
considered significant. Statistical calculations were car-




MTX-LPD lesions were analyzed in 207 nodal regions and
117 extranodal regions and identified in 75 nodal ana-
tomic regions (36.2 %) and 17 extranodal anatomic re-
gions (14.5 %). 18F-FDG PET/CT was superior to MDCT
at detecting both nodal and extranodal regions. 18F-FDG
PET/CT scanning could detect 70/75 nodal (93.3 %) and
11/17 extranodal anatomic regions (64.7 %), whereas
MDCT detected only 45/75 nodal (60.0 %) and 9/17
extranodal anatomic regions (52.9 %). Consequently, the
sensitivity, specificity, and accuracy (Table 3.) for the
detection of lesions were 83/92 (90.2 %), 226/232 (97.4 %),
and 309/324 (95.4 %), respectively, for 18F-FDG PET/CT
and 55/92 (59.8 %), 220/232 (94.8 %), and 275/324
(84.9 %), respectively, for MDCT (Table 4). The diagnostic
accuracy of FDG-PET/CT was significantly higher than
that of MDCT (p < 0.002). In the evaluation of interob-
server agreement, discordant assessments were observed
for five nodal regions and none of the extranodal regions
in the FDG PET/CT reading, and for 30 nodal regions
and five extranodal regions in the MDCT reading.
There were five extranodal lesions that 18F-FDG PET/
CT scanning could identify but MDCT could not; one in
the bowel, one in bone (Fig. 1), one in the tonsil and two
in the gingiva. The FN lesions were five nodal regions;
both sides of the infraclavicular, the right axilla, and both
sides of the inguinal and femoral regions. Four extrano-
dal regions were FN; three in skin detected by only
visual examination and one in lung. There were six FP
lesions; lung, bone and four nodal lesions in the axilla,
hilar, mesenteric, and iliac regions. One was a lung
lesion that showed focal 18F-FDG uptake; this was pneu-
monitis. A second FP lesion was on bone that had focal
18F-FDG uptake, which was shown to be negative by
bone marrow aspiration cytology. The other FPs identi-
fied by 18F-FDG PET/CT scanning were four nodal
lesions that include the axilla, hilar, mesenteric and iliac
regions with asymmetric 18F-FDG uptake.
18F-FDG PET parameters
The medians and ranges of the 18F-FDG PET parameters
were as follows. SUVmax: 10.3 (range 0–47.1), WBMTV:
33.5 ml (range 0–362.6 ml), and WBTLG: 167.0 ml
(range 0–2180.9 ml). The differences in the metabolic
parameters between the CR patients and the non-CR pa-
tients are presented in Table 5. There was no significant
association between 18F-FDG PET/CT parameters and
the CR patients.
Discussion
The results of this study demonstrated that the diagnos-
tic accuracy of 18F-FDG PET/CT for identifying MTX-
LPD lesions was significantly higher than that of MDCT
scans, and we observed that none of the 18F-FDG PET
parameters, i.e., SUVmax, WBMTV, and WBTLG could
be used to distinguish responders from non-responders
to the withdrawal of MTX.
18F-FDG PET/CT is widely accepted as the most sensi-
tive imaging modality for staging, monitoring the
response, and predicting the prognosis for various
lymphomas [11–14, 25, 26]. The usefulness of 18F-FDG
PET/CT scans for assessing MTX-LPD has been investi-
gated [4–6]. Our present findings revealed that 18F-FDG
PET/CT was more successful than MDCT in detecting
nodal and extranodal malignant lesions, which is con-
sistent with other types of lymphomas. The 18F-FDG
PET/CT scans will correctly alter the initial disease stage
for some patients and follow the distribution of lesions.
These data support the important role of 18F-FDG PET/
CT scans for the staging of MTX-LPD.
There were five extranodal lesions that only 18F-FDG
PET/CT scanning could identify: one bowel, one bone
Table 4 Comparison of 18F-FDG PET/CT and CT for the region-
based detection of nodal and extranodal disease
Region-based analysis Diagnostic performance
TP FP TN FN Total Sensitivity Specificity Accuracy
FDG-
PET/CT












FN false negative, FP false positive, TN true negative, TP true positive
Table 3 Definitions of diagnostic test parameters
Diagnostic test parameter Definition
Sensitivity TP/(TP + FN)
Specificity TN/(TN + FP)
Accuracy (TP + TN)/(TP + FP + FN + TN)
FN false negative, FP false positive, TN true negative, TP true positive
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(Fig. 1), one tonsil, and two gingival lesions. For staging
patients with Hodgkin lymphoma or aggressive NHL,
Schaefer et al. reported that PET/CT was more sensitive
and specific than even contrast-enhanced CT, and they
suggested that PET/CT without intravenous contrast
media was sufficient [24]. In the present study, the pro-
tocols of the MDCT scans were not the same; some
patients underwent non-contrast CT. However, even
with a contrast agent, those were difficult to distinguish
from normal structures by the anatomical CT scans, and
the artifact from the prosthesis made the diagnostic
reading of the oral cavity difficult.
Of the nine malignant lesions that 18F-FDG PET/CT
scanning failed to detect, the five nodal regions were
both sides of the infraclavicular, the right axilla and both
sides of the inguinal and femoral regions, and the four
extranodal regions were three skin sites detected by vis-
ual examination and one lung lesion which was difficult
to detect by CT in the expiratory state. These lesions
were too small for the detection of FDG uptake, or the
uptake of these lesions was considered physiological
uptake because of symmetrical distributions. The PET/
CT scans also detected six FP lesions: lung, bone and
four nodal lesions in the axilla, hilar, mesenteric, and
iliac regions.
MTX withdrawal and observation for a short period
should be considered in the initial management of
patients who develop LPD while on MTX therapy, be-
cause more than half of the deaths were due to compli-
cations from chemotherapy and other causes (except
disease progression) [15, 16]. In their review of the
MTX-LPD literature, Ichikawa et al. noted that CR most
commonly occurred within 4 weeks after MTX
Fig. 2 Representative case of complete response group. Maximum
intensity projection images of 18F-FDG PET/CT at (a) initial
examination, and (b) 4 months after from withdrawal of MTX were
displayed. Multiple 18F-FDG -avid lesions was found in the whole
body (SUVmax 9.2, WBMTV 44.3 ml, WBTLG 191.1 ml). The patient
underwent 18F-FDG PET/CT again after cessation of MTX, which
showed that multiple lesions on PET completely resolved. Regarding
the metabolic activity of inflammation with Rheumatoid Arthritis,
abnormal 18F-FDG uptake was appeared in large joints in a second
PET/CT scans
Table 5 Predictive value of each status
CR (n = 9) non-CR (n = 6) p-value
Duration of MTX (month) 50 (7–172) 81 (40–234) 0.19
Dose of MTX (mg/week) 8.0 (4.0–16.0) 9.0 (6.0–16.0) 0.14
Number of sites 5 (1–99) 3 (1–41) 0.30
SUVmax 9.2 (2.8–47.1) 13.9 (0–24.9) 0.21
WBMTV (ml) 26.6 (0–362.6) 22.7 (0–250.1) 0.36
WBTLG (ml) 111.6 (0–2180.9) 152.1 (0–1052.1) 0.25
sIL-2R (U/ml) 758 (310–3157) 795 (259–5861) 0.16
CR complete response, MTX methotrexate, sIL-2R soluble interleukin-2 receptor,
SUVmax maximum of standardized uptake value, WBMTV whole body
metabolic tumor volume, WBTLG whole body total legion glycolysis
Fig. 1 The PET/CT-positive and MDCT-negative case. Bone marrow involvement with obvious FDG uptake was detected by PET/CT (a). The MDCT
scan showed no mass lesion (b)
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withdrawal, and they therefore proposed that observa-
tion for 1–2 months without any treatment but with
withdrawal of immunosuppressant therapy is indicated if
the patient’s general condition allows [16].
In the present analysis, nine patients achieved spontan-
eous remission of their LPD after MTX withdrawal (Fig. 2).
Other studies also showed the potential usefulness of the
MTV as a parameter for the prediction of clinical out-
comes in several types of lymphoma [11, 12, 26, 27]. How-
ever, our present findings suggest that the metabolic
activity could not predict the prognostic outcome when it
comes to MTX-LPD, possibly because its behavior differs
from that of other types of lymphoma (Fig. 3).
This study has some limitations. The retrospective nature
of the study is a critical limitation in its generalization. The
number of patients (n = 15) is small, because of the rela-
tively low incidence of the disease. Another limitation is
the use of clinical follow-up with additional imaging studies
as the standard of reference, which may lead to a false clas-
sification of the lesions. Biopsies of every suggestive lesion
are neither ethical nor recommended in routine clinical
practice. Benign lesions, such as focal inflammation, that
were resolved on follow-up imaging studies could have
been falsely regarded as TPs. Conversely, malignant lesions
with lower 18F-FDG-avidity could have been falsely
regarded as negative. These misdiagnoses might have
compromised the sensitivity of the 18F-FDG PET/CT
scanning. Existing published studies share the same
limitations [20, 28–31].
Conclusion
18F-FDG PET/CT was a useful tool to detect MTX-LPD
lesions. However, none of the 18F-FDG PET/CT parame-
ters before MTX withdrawal could predict a CR after
the withdrawal of MTX. MTX-LPD patients should be
carefully monitored using follow-up 18F-FDG PET/CT
regardless of the disease metabolic condition.
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intensity projection images of 18F-FDG PET/CT at initial examination (a),
and second examination at 6 months after MTX withdrawal (b) were
shown. At the initial examination, an 18F-FDG-avid lesion was found at
left neck (c; SUVmax 7.3, WBMTV 8.6 ml, WBTLG 42.7 ml). It was
disappeared at the second examination after MTX withdrawal. However,
at the second scan a recurrent lesion was found at left supraclavicular
fossa (d) and radiotherapy was enforced. 18F-FDG uptake was confirmed
at bilateral wrist joints, reflecting the reactivation of RA due to withdrawal
of MTX
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